We are live on ! Find out more
AVIR icon

Atea Pharmaceuticals
AVIR

142 hedge funds and large institutions have $1.99B invested in Atea Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 42 increasing their positions, 31 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

235% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 17

58% more capital invested

Capital invested by funds: $1.26B → $1.99B (+$727M)

38% more funds holding

Funds holding: 103 → 142 (+39)

35% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 31

10% more call options, than puts

Call options by funds: $13M | Put options by funds: $11.8M

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

2.52% less ownership

Funds ownership: 71.18% → 68.67% (-2.5%)

Holders
142
Holders Change
+39
Holders Change %
+37.86%
% of All Funds
2.49%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
57
Increased
42
Reduced
31
Closed
17
Calls
$13M
Puts
$11.8M
Net Calls
+$1.23M
Net Calls Change
+$2.25M

Top Buyers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
+$45.9M
2
BlackRock
BlackRock
New York
+$17.9M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$17.9M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$9.86M
5
Goldman Sachs
Goldman Sachs
New York
+$9.24M

Top Sellers

Rank Fund Capital Flow
1
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
-$53.1M
2
CAM
Cormorant Asset Management
Massachusetts
-$41.1M
3
AICPI
ABG Innovation Capital Partners III
Hong Kong
-$27.2M
4
UBS Group
UBS Group
Switzerland
-$17M
5
OFM
Omega Fund Management
Massachusetts
-$16.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
26
Wells Fargo
California
$9.88M +$7.81M +281,441 +101,238%
N
27
Nuveen
North Carolina
$9.42M -$931K -33,550 -11%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$9.09M +$1.75M +62,999 +32%
Voloridge Investment Management
29
Voloridge Investment Management
Florida
$9.03M -$583K -21,034 -8%
WP
30
Woodline Partners
California
$6.5M -$70.5K -2,540 -1%
FCM
31
Frontier Capital Management
Massachusetts
$6.29M +$4.97M +179,346 New
Arrowstreet Capital
32
Arrowstreet Capital
Massachusetts
$6.26M +$1.32M +47,695 +36%
EA
33
Emerald Advisers
Pennsylvania
$6.1M +$4.82M +173,950 New
CAM
34
Congress Asset Management
Massachusetts
$5.88M +$373K +13,435 +9%
OFM
35
Omega Fund Management
Massachusetts
$5.77M -$16.2M -582,291 -78%
DCM
36
Discovery Capital Management
Connecticut
$5.71M +$4.52M +162,800 New
GTC
37
Ghost Tree Capital
New York
$5.26M +$4.16M +150,000 New
PI
38
Putnam Investments
Massachusetts
$4.96M +$3.93M +141,520 New
Russell Investments Group
39
Russell Investments Group
United Kingdom
$4.93M +$3.91M +140,818 +8,303%
Canada Pension Plan Investment Board
40
Canada Pension Plan Investment Board
Ontario, Canada
$4.84M +$3.83M +138,000 New
EMFAT
41
Emerald Mutual Fund Advisers Trust
Pennsylvania
$4.34M +$3.44M +123,877 New
SCM
42
Soleus Capital Management
Connecticut
$4.12M +$3.26M +117,600 New
Millennium Management
43
Millennium Management
New York
$4.05M +$3.21M +115,671 New
Norges Bank
44
Norges Bank
Norway
$3.83M -$14.9M -537,267 -83%
PAMS
45
Pictet Asset Management (Switzerland)
Switzerland
$3.76M +$2.98M +107,306 New
SSA
46
Schonfeld Strategic Advisors
New York
$3.66M +$2.9M +104,378 New
MIM
47
Monashee Investment Management
Massachusetts
$3.51M -$1.8M -65,000 -39%
CM
48
CM Management
Florida
$3.51M +$277K +10,000 +11%
SAMH
49
Shanda Asset Management Holdings
British Virgin Islands
$3.51M +$2.77M +100,000 New
Citadel Advisors
50
Citadel Advisors
Florida
$3.49M +$1.16M +42,001 +73%
1
2
3 4 5

AVIR Hedge Fund Activity: Q3 2021 in Review

142 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q3 2021, worth a combined $1.99B — up 58% from $1.26B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new AVIR positions and 17 closed out — a net gain of 40 holders — while 42 added to existing stakes and 31 trimmed.

The largest buyer was Viking Global Investors, opening a new position worth an estimated $45.9M. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $53.1M.

  • 142 institutional investors held Atea Pharmaceuticals (AVIR) as of Q3 2021, up from 103 in Q2 2021.
  • Funds reported $1.99B of Atea Pharmaceuticals stock for Q3 2021, up 58% quarter-over-quarter.
  • 57 funds opened new Atea Pharmaceuticals positions in Q3 2021 and 17 closed out, a net change of +40 holders.
  • The largest Atea Pharmaceuticals buyer in Q3 2021 was Viking Global Investors, an estimated $45.9M added.
  • The largest Atea Pharmaceuticals seller in Q3 2021 was Bain Capital Life Sciences Investors, an estimated $53.1M sold.

Based on aggregated 13F filings for Q3 2021.